Загрузка...
BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer
PARP inhibition is known to be an effective clinical strategy in BRCA-mutant cancers, but PARP inhibition has not been applied to BRCA-proficient tumors. Here we show synergy of BET bromodomain inhibition with PARP inhibition in BRCA-proficient ovarian cancers due to mitotic catastrophe. Treatment o...
Сохранить в:
| Опубликовано в: : | Cell Rep |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5745042/ https://ncbi.nlm.nih.gov/pubmed/29262321 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2017.11.095 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|